Expect roughly £200 to £600 for a basic polyclonal project, £2,500 to £8,000 for a standard monoclonal, and £8,000 upwards for recombinant antibody development, though final figures depend heavily on scope and validation. These figures assume research-grade production rather than clinical-scale manufacturing, which sits on an entirely different cost scale. Before committing to a supplier, request an itemised quote listing every deliverable and validation tier, or consider a scientist-led sourcing service to help scope the brief accurately.
TL;DR:
- Custom antibody prices range from about £200 to over £8,000, depending on type, scope, validation tier, and purification grade.
- Quotes often exclude antigen synthesis, conjugation, or licensing fees, which may add significant costs and vary by supplier.
- Lead times increase from a few weeks for polyclonal antibodies to several months for recombinant monoclonals, with higher costs for expedited options.
- When comparing quotes, it is crucial to examine deliverables, validation evidence, validation tiers, and IP terms to avoid hidden fees.
- Working with a scientist-led sourcing service can help clarify project scope and secure more accurate, comparable cost estimates.
Table of Contents
- Price breakdown by antibody type: what researchers usually pay
- What suppliers mean by a quoted package
- Major factors that change cost
- Timelines: typical lead times and milestones for each antibody route
- How to solicit and compare quotes for custom antibodies
- Hidden and additional costs to budget for
- Fixed price versus milestone-based billing
- How ABMIUM approaches costing and reproducibility
- Getting a scoped quote for your project
- Sources
- FAQ
Price breakdown by antibody type: what researchers usually pay
Custom antibody pricing splits broadly into three tiers, each shaped by the biology involved and the manufacturing route chosen. Polyclonal antibodies remain the cheapest entry point because they rely on a straightforward immunisation and bleed schedule, typically using a rabbit or goat host. A basic package usually includes crude serum or a single round of affinity purification, with minimal validation beyond a title check.
Monoclonal antibodies occupy a much wider band, largely because hybridoma generation involves cell fusion, clone screening, and stability testing across multiple candidates before a final clone is selected. Recombinant monoclonal development, which bypasses hybridoma cell lines in favour of cloning and expressing antibody genes directly, tends to carry higher upfront costs for library screening and vector construction. That investment often pays off in reproducibility, since a defined genetic sequence removes the batch-to-batch drift that can affect hybridoma-derived lines.
Industry pricing pages describing research-grade projects show costs ranging from a few hundred pounds for simple polyclonal packages to several thousand for monoclonal projects with broader screening, though exact numbers vary by supplier and scope. To make sense of any quote you receive, it helps to map it against typical inclusions at each tier:
- Basic polyclonal: crude or partially purified serum, single host, minimal documentation.
- Standard monoclonal: hybridoma fusion, screening of several clones, one purified antibody format.
- Recombinant monoclonal: sequence-defined construct, expression in a mammalian or bacterial system, higher-purity output with batch consistency built in.
None of these bands is fixed. A monoclonal project with extensive cross-reactivity testing against multiple species will sit well above a project asking only for basic ELISA reactivity.
What suppliers mean by a quoted package
A quote is only useful if you can see exactly what it buys. Suppliers structure custom antibody packages around a defined set of deliverables and an agreed validation tier, and comparing two quotes only makes sense once you know both cover the same ground.
- Deliverables: most packages specify whether you receive crude serum, purified IgG, or affinity-purified antibody, along with aliquot volumes and a certificate of analysis.
- Validation tiers: entry-level packages usually include a screening ELISA; higher tiers add western blot, immunohistochemistry, or flow cytometry confirmation, each adding cost and turnaround time.
- Antigen design and synthesis: peptide or protein antigen preparation is frequently billed separately, particularly when peptide synthesis is required to generate the immunogen.
- Conjugation and functional testing: labelling an antibody with a fluorophore or enzyme, or confirming function in a specific assay, typically sits outside the base package.
- IP and licensing terms: some suppliers retain rights to hybridoma cell lines or sequence data unless you negotiate exclusive ownership, which can affect price.
Reading a quote line by line against this list quickly reveals whether a low headline price is hiding gaps you will need to pay for later.
Major factors that change cost
Two quotes for what sounds like the same project can differ by a wide margin, and the reasons usually trace back to a handful of technical choices.
- Antigen type and complexity: a short synthetic peptide costs less to prepare than a full recombinant protein antigen, and custom synthesis adds a separate line item.
- Host species and clonality: rabbit polyclonal projects are generally cheaper than monoclonal work in mice or rats, partly because polyclonal immunisation schedules are simpler.
- Screening breadth: monoclonal projects that screen a larger number of hybridoma clones for specificity cost more than a project accepting the first viable clone.
- Purification grade: affinity-purified antibody with documented yield costs more than crude serum, reflecting the extra processing steps.
- Contractual terms: exclusive IP ownership, repeat-order pricing, and scale-up allowances are often negotiated separately from the base development fee.
Pro Tip: Ask suppliers to quote antigen design and synthesis as a separate line item from antibody generation. It lets you see exactly where your budget is going and makes it easier to compare across vendors.
Target and epitope selection also matters more than many researchers expect. Basic explainers on gene expression are a useful starting point when deciding which region of a target protein will make the most specific and cost-effective immunogen.
Timelines: typical lead times and milestones for each antibody route
Lead times vary by antibody type and directly affect when payments fall due.
- Peptide-based polyclonal projects: antigen synthesis, immunisation, and a series of boosts and bleeds typically span several weeks to a few months before final serum delivery.
- Hybridoma monoclonal projects: fusion, clone screening, and stability testing extend timelines further, since hybridoma generation requires successive rounds of subcloning before a stable line is confirmed.
- Recombinant antibody projects: library selection or phage display, followed by cloning and expression optimisation, adds additional weeks but produces a sequence-defined, reproducible output.
Expedited timelines usually carry a premium, and most suppliers tie payments to milestones such as antigen delivery, first bleed, or clone confirmation rather than billing the full amount upfront.
How to solicit and compare quotes for custom antibodies
A well-structured enquiry saves time and produces quotes you can genuinely compare. Include your target sequence or antigen details, intended applications such as western blot or immunohistochemistry, and required species reactivity in your first message to any supplier.
- Ask for deliverables in writing: confirm exactly what format and volume of antibody you will receive.
- Request validation evidence: ask whether the supplier can show example data from comparable projects, not just a generic assay list.
- Clarify repeat-order pricing: find out what a second batch costs before you commit to the first.
- Confirm IP terms upfront: establish who owns the hybridoma line or sequence data.
Pro Tip: Treat vague deliverables, no example validation data, and an absent milestone schedule as red flags. A supplier confident in its process will set out both clearly before you sign anything.
Hidden and additional costs to budget for
The headline price on a custom antibody quote rarely covers everything you will end up paying. Shipping antibody or antigen material, particularly with cold-chain requirements, is frequently billed separately and can vary considerably depending on destination and packaging needs. Import duties or local taxes may apply depending on where the antibody is manufactured and shipped, and these are rarely itemised in an initial quote.
Re-customisation fees are another common surprise: if the first clone or antiserum fails to meet your specificity requirements, some suppliers charge for a repeat immunisation round or additional screening rather than treating it as covered by the original fee. Conjugation to a label after the fact, additional validation beyond the agreed tier, and extra aliquoting or reformatting for a specific buffer also tend to appear as add-ons once a project is underway.
Storage and rush fees are worth checking too. A supplier holding finished antibody in long-term storage, or one asked to compress a normal timeline, may apply charges not visible in the base quote. The safest approach is to ask directly whether the quoted figure is genuinely final or whether any of these categories could apply to your project, and to get the answer in writing before the work begins.
Fixed price versus milestone-based billing
Suppliers generally price custom antibody projects one of two ways, and the choice affects both cash flow and risk. A fixed-price model quotes one total figure for the whole project, which is simpler to budget against but can obscure what happens if a clone fails or additional screening is needed.
Milestone-based billing splits payment across defined stages, such as antigen delivery, first bleed or fusion, clone confirmation, and final delivery. This approach ties payment to progress and gives you a natural point to pause or renegotiate if early results are disappointing, though it requires more oversight from your side to track what has actually been delivered at each stage.
Neither model is inherently better, but milestone billing tends to suit higher-cost monoclonal and recombinant projects where the risk of early failure is greater, while fixed pricing works well for simpler polyclonal packages with a narrow scope. Whichever model a supplier proposes, ask them to define exactly what triggers each payment and what happens if a milestone is not met.
How ABMIUM approaches costing and reproducibility
ABMIUM MATCH offers scientist-led sourcing that helps researchers scope a project brief before it ever reaches a supplier, which removes many of the ambiguous line items that inflate quotes later. Traceable documentation and structured validation evidence reduce the risk of a failed run turning into an unplanned repeat cost. In practice, this means structuring your brief so that target, host, and validation requirements are defined upfront, allowing suppliers to return quotes that are genuinely comparable rather than differently scoped estimates dressed up as the same service.
— Veron
Getting a scoped quote for your project
A clear brief is the single biggest lever you have over final cost, and this is where working directly with ABMIUM saves time compared with chasing multiple vendor forms. Alongside its catalogue of primary antibodies, ELISA kits and recombinant proteins, ABMIUM offers a dedicated Custom Antibody Service alongside custom protein and ELISA development.
When you enquire, include your target sequence or antigen, intended application, and species reactivity requirements, the same details any supplier needs to scope a project properly. In return, a provider will work to return itemised deliverables, a defined validation plan, and a realistic timeline rather than a single opaque figure.
- Custom Antibody Service, Custom Protein Services and Custom ELISA Development are available through the same enquiry process.
- A scientist-led sourcing service helps you compare suitable products or scoped custom projects before you commit.
- Independent validation services and mass spectrometry are available through specialist collaborators for added confidence in your final antibody.
Visit the custom services page to submit your project details and request a scoped quote.
Sources
Figures and process context in this article draw on peer-reviewed analyses of antibody manufacturing economics, reference entries on hybridoma technology and peptide synthesis, and published market data on therapeutic monoclonal antibody pricing.
- The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities | BioDrugs
- Cost and supply considerations for antibody therapeutics
- Peptide synthesis — ScienceDirect Topics
- Hybridoma — Britannica
FAQ
How much does it cost to develop a custom antibody?
Costs typically range from around £200 to £600 for a basic polyclonal antibody up to £8,000 or more for a recombinant monoclonal, depending on host species, purification grade, and validation requirements. Requesting an itemised quote is the only reliable way to confirm what a specific project will cost.
How much does an antibody cost?
An off-the-shelf research antibody from a catalogue typically costs far less than a custom-developed one, since the antigen work, immunisation, and screening are already complete. Custom projects cost more because they involve bespoke antigen design and dedicated development time for your specific target.
How much does antibody therapy cost?
Antibody therapy operates on an entirely different cost scale to research-grade custom antibody production, with published analysis reporting an average cost of around $127,430 per course or year for therapeutic monoclonal antibodies. This reflects clinical manufacturing, regulatory, and biomanufacturing costs that do not apply to research antibody development.
How much do monoclonal antibodies cost per gram?
Per-gram pricing for monoclonal antibodies varies widely and is generally only relevant at manufacturing or therapeutic scale rather than for a typical research project. Cost and supply analyses point to biomanufacturing format and process economics as the main drivers of per-gram cost, which differ substantially from research-grade project pricing.